Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Prostate cancer
is one of the most common malignancies in males throughout the world, and its incidence is increasing in Asian countries. We carried out a genome-wide association study and replication study using 4,584 Japanese men with
prostate cancer
and 8,801 control subjects. From the thirty-one associated SNPs reported in previous genome-wide association studies in European populations, we confirmed the association of nine SNPs at P < 1.0 x 10(-7) and ten SNPs at P < 0.05 in the Japanese population. The remaining 12 SNPs showed no association (P > 0.05). In addition, we report here five new loci for
prostate cancer
susceptibility, at 5p15 (lambda-corrected probability P(GC) = 3.9 x 10(-18)), GPRC6A/RFX6 (P(GC) = 1.6 x 10(-12)), 13q22 (P(GC) = 2.8 x 10(-9)), C2orf43 (P(GC) = 7.5 x 10(-8)) and
FOXP4
(P(GC) = 7.6 x 10(-8)). These findings advance our understanding of the genetic basis of prostate carcinogenesis and also highlight the genetic heterogeneity of
prostate cancer
susceptibility among different ethnic populations.
...
PMID:Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. 2067 98
In the past twenty-five years, over 700 case-control association studies on the risk of
prostate cancer
have been published worldwide, but their results were largely inconsistent. To facilitate following and explaining these findings, we performed a systematic meta-analysis using allelic contrasts for gene-specific SNVs from at least three independent population-based case-control studies, which were published in the field of
prostate cancer
between August 1, 1990 and August 1, 2015. Across 66 meta-analyses, a total of 20 genetic variants involving 584,100 subjects in 19 different genes (KLK3, IGFBP3, ESR1, SOD2, CAT, CYP1B1, VDR, RFX6, HNF1B, SRD5A2, FGFR4, LEP, HOXB13, FAS,
FOXP4
, SLC22A3, LMTK2, EHBP1 and MSMB) exhibited significant association with
prostate cancer
. The average summary OR was 1.33 (ranging from: 1.016-3.788) for risk alleles and 0.838 (ranging from: 0.757-0.896) for protective alleles. Of these positive variants,
FOXP4
rs1983891, LMTK2 rs6465657 and RFX6 rs339331 had not been previously meta-analyzed. Further analyses with sufficient power design and investigations of the potential biological roles of these genetic variants in
prostate cancer
should be conducted.
...
PMID:Systematic meta-analyses of gene-specific genetic association studies in prostate cancer. 2696 44
Prostate cancer
(PCa) is one of the major men malignancies worldwide. Long noncoding RNAs (lncRNAs) have been reported as essential regulators in human cancers, including PCa. In the present study, lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) was found to be highly expressed in TCGA PCa samples. Upregulation of
FOXP4
-AS1 was further validated in 64 PCa tissues and predicted poor prognosis in patients with PCa. Functionally, high
FOXP4
-AS1 level was associated with increased cell proliferation and decreased cell apoptosis, indicating that
FOXP4
-AS1 exerted oncogenic functions in the tumorigenesis of PCa. Furthermore,
FOXP4
-AS1 was located in the cytoplasm of PCa cell lines and positively regulated
FOXP4
. LncRNAs can exert their functions by cooperating with their nearby genes. Mechanistically,
FOXP4
-AS1 post-transcriptionally regulated
FOXP4
by acting as a competing endogenous RNA (ceRNA) in PCa to sponge miR-3184-5p. Considering the upregulation of both
FOXP4
-AS1 and its nearby gene
FOXP4
, we further detected the coactivator of
FOXP4
-AS1 and
FOXP4
. Mechanism analysis indicated that paired box 5 (PAX5) transcriptionally activated
FOXP4
-AS1 and
FOXP4
in PCa. Collectively, we determined that PAX5-induced upregulation of
FOXP4
-AS1/
FOXP4
axis promoted tumorigenesis of PCa.
...
PMID:LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4. 3120 7
In recent years, circular RNAs (circRNAs) have been identified to be essential regulators of various human cancers. However, knowledge of the functions of circRNAs in
prostate cancer
remains very limited. The correlation between circABCC4 and human cancer is largely unknown. This study aims to investigate the biological functions of circABCC4 in
prostate cancer
progression and illustrate the underlying mechanism. We found that circABCC4 was remarkably up-regulated in
prostate cancer
tissues and cell lines and promoted
FOXP4
expression by sponging miR-1182 in
prostate cancer
cells. CircABCC4 knockdown markedly suppressed
prostate cancer
cell proliferation, cell-cycle progression, migration and invasion in vitro. Furthermore, silencing of the circRNA also delayed tumor growth in vivo. Taken together, our findings indicated that circABCC4 facilitates the malignant behaviour of
prostate cancer
by promoting
FOXP4
expression through sponging of miR-1182. The circABCC4-miR-1182-
FOXP4
regulatory loop may be a promising therapeutic target for
prostate cancer
intervention.
...
PMID:Circular RNA circABCC4 as the ceRNA of miR-1182 facilitates prostate cancer progression by promoting FOXP4 expression. 3127 Sep 53